BERMUDA-BUSINESS-DEVELOP
24.5.2023 16:10:33 CEST | Business Wire | Press release
Suzanne Johnson, Senior Advisor, United Nations (UN) Global Compact Ocean Stewardship Coalition, is the latest addition to the impressive list of speakers at the second annual Bermuda Climate Summit, presented by the Bermuda Business Development Agency (BDA), in partnership with KBRA.
Bermuda’s Deputy Premier, The Hon. Walter Roban, JP, MP, will open the Summit on June 26 with a conversation with Jim Nadler, President & CEO, KBRA. Another luncheon keynote will be given by Joshua Rosenberg, Chief Risk Officer, Federal Reserve Bank of New York on June 27.
Suzanne Johnson said, “It will be a pleasure to discuss the UN Global Compact work to advance a more sustainable ocean economy at the Bermuda Climate Summit. I look forward to discussing how ocean industry and finance can help to address the climate and nature crisis with financial service executives, academics and international regulators in attendance at the summit.”
David Hart, CEO, BDA said, “We are honoured to have a leading expert like Suzanne Johnson giving a keynote at our Bermuda Climate Summit joining an already impressive line-up. It is sure to be an incredible two days of informative and collaborative discussions not just about climate related challenges, but how Bermuda is the perfect place to create and deliver innovative solutions to the global marketplace.”
We are strongly encouraging prospective delegates from overseas to secure their room and receive special rates at our event hotel, the Hamilton Princess & Beach Club, by booking online prior to May 25. Click here to register – this year’s theme is: ‘Bermuda - Climate Central’.
Stay tuned to the BDA website for agenda updates– sessions confirmed to date include: Impact of a Changing Climate on Atlantic Hurricane Frequency and Severity moderated by Marla Pourrabbani, Data Scientist, Senior Manager, ESG and Sustainability, Deloitte, with panellists: Dr. Pete Dailey, Head of Research, Aeolus, Liz Henderson, Co-Head Catastrophe Analytics, Executive Managing Director, Reinsurance Solutions, Aon, Dr. Peter Sousounis, Vice President/Director Climate Change Research, Verisk, and Craig Tillman, President, RenaissanceRe Risk Sciences.
How Do You Measure Environmental Impact? will be moderated by Barclay Palmer, Executive Editor and Head of Strategy, Climate and Capital Media, and include panellists, Kevin Cei, Climate and Weather Solutions Executive, Jupiter Intelligence, Michele DeMers, CEO, Boundless Impact Research & Analytics, and Keith Pitts, SVP, Sustainability and Regulatory Strategy, Bioceres Crop Solutions.
What’s Ahead in the United States? will be moderated by John Huff, President & CEO, Association of Bermuda Insurers and Reinsurers (ABIR) and include panellists, Ricardo Lara, Insurance Commissioner, California Department of Insurance, Co-Chair of the NAIC Climate and Resiliency Task Force and Lori Wing-Heier, Director, Alaska Division of Insurance, Co-Chair of the NAIC Climate and Resiliency Task Force.
ESG: Where Does the Road Go From Here? will be moderated by Victoria Harman, Founder and Principal, VL Harmon Advisors, and will include panellists, Prabh Banga, VP Sustainability, Aecon, Harry Masters, Director, Advancing Green, Caroline McGill, Principal, Sustainability, and Impact Investment Strategy, Hillbreak and Patrick Welch, Chief ESG and Ratings Policy Officer, KBRA.
Green Opportunities, an Investor’s Perspective will be moderated by Bill Cox, Global Head of Corporate, Financial and Government Ratings, KBRA, with panellists Alexandra Cooley, Chief Investment Officer, Nuveen, Andrea Griffin, Global Head of Responsible Investments Specialists, HSBC Asset Management and Steve Hatfield, US Head of ESG, Carlyle Group.
Global Climate Risk will be moderated by Jeane Nikolai, Director of Energy, Government of Bermuda, and will include panellists Dr. Mark Guishard, Chartered Meteorologist, Adjunct Scientist and Trustee, BIOS, Dr. Raveem Ismail, Head of Parametric Underwriting, Africa Specialty Risks (ASR Re) and Dr. Simon Young, Senior Director, Willis Towers Watson.
Biodiversity: Our Strongest Natural Defense Against Climate Change will be moderated by Slav Gatchev, Managing Director, Sustainable Debt, The Nature Conservancy, with panellists, Osho Jha, CEO & Co-Founder at dClimate, Co-Founder & Chief Data Scientist at Arbol Inc, James Kench, Head of Insurance, KITA, and Natalia Moudrak, Climate Resiliency Leader, AON.
Climate and the Evolving Regulatory and Reporting Landscape will be moderated by Suzanne Williams-Charles, Director of Policy and Regulation, Corporate Secretary and Data Privacy Officer, ABIR, and feature panellists Ralf Kuerzdoerfer, Deputy Director, Supervision (Insurance), Bermuda Monetary Authority, Sohini Chowdhury, Senior Director, Moody’s Analytics, Ricardo Lara, Insurance Commissioner, California Department of Insurance and Arnaud van Dijk, Partner, ESG, KPMG.
The U.S. Federal Flood Programme and the (Re)Insurance Sector, will be moderated by Peter Giacone, Global Head of Insurance, KBRA and include panelists, Chris Brown – Partner, Mindset, Chlora Lindley-Myers, NAIC President and Director of the Missouri Department of Commerce and Insurance, and Andy Neal, Managing Director, Public Private Partnerships, Aon.
Net Zero? will be moderated by Miqdaad Versi, Head of ESG, Oxbow Partners, UK, and feature panelists Rachael Dalheise. Head of Sustainability, Convex, Andrew MacFarlane, Head of Climate, AXA XL, a Division of AXA, Andrew Smith, Chief Risk and Sustainability Officer, Conduit Re and Dr. Steve Smith- Head of Research & Development, Vantage.
The Power of Partnerships, which will be moderated by Jeff Manson, SVP Underwriting and Head of Global Public Sector Partnership, Renaissance Re Ltd, and will include panellists, Ekhosuehi Iyahen, Secretary General, Insurance Development Forum, Sid Miller, Director, Climate Wise, Rebekah Clement, Head of Sustainability, Lloyds, and Chair of SMI Climate Action Committee, and Tim Nielander, Founder and President, GP3 Institute.
Deep Ocean Solutions will be moderated by William Curry, President and CEO, BIOS, and feature panelists Neil Eckert, Executive Chairman, Conduit Re, Irene Polnyi- Additional Ventures Affiliate, and Mallory Ringham, PhD Chemical Oceanography, Ebb Carbon.
The BDA is grateful for the continued support of our headline sponsor KBRA, as well as: diamond sponsor Conduit Re; platinum sponsor Aon; gold sponsors Deloitte, Fidelis and Hub Culture; and silver sponsors Aeolus, Aspen, AXA XL, Belco, and KPMG. Our supporting sponsors are Butterfield and HSBC. Our media partners are The Insurer, Insurance Insider and Bermuda:Re+ILS. Our spirits partner is Goslings. Other sponsorship opportunities are still available; please e-mail bermudaclimate@bda.bm if you wish to participate.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005581/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom